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Omega-3 (or n-3) polyunsaturated fatty acids (PUFAs) and their metabolites are natural ligands for peroxisome proliferator
receptor activator (PPAR)γ and, due to the eﬀects of PPARγ on cell proliferation, survival, and diﬀerentiation, are potential
anticancer agents. Dietary intake of omega-3 PUFAs has been associated with a reduced risk of certain cancers in human
populationsandinanimalmodels.Invitrostudieshaveshownthatomega-3PUFAsinhibitcellproliferationandinduceapoptosis
in cancer cells through various pathways but one of which involves PPARγ activation. The diﬀerential activation of PPARγ and
PPARγ-regulated genes by speciﬁc dietary fatty acids may be central to their distinct roles in cancer. This review summarizes
studies relating PUFAs to PPARγ and cancer and oﬀers a new paradigm relating an n-3 PUFA through PPARγ to the expression of
the cell surface proteoglycan, syndecan-1, and to the death of cancer cells.
Copyright © 2008 I. J. Edwards and J. T. O’Flaherty. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
1. INTRODUCTION
The peroxisome proliferator-activated receptor (PPAR) fam-
ily of nuclear receptors comprises three distinct gene prod-
ucts,PPARα,β/δ,andγ,thatdiﬀerinligandspeciﬁcity,tissue
distribution, and developmental expression [1–3]. PPARs
demonstrate a relatively high level of constitutive transcrip-
tional activity which is further increased upon binding their
activating ligands [4–7]. These ligands are primarily long
chain unsaturated and polyunsaturated fatty acids (PUFAs)
and certain metabolites of these fatty acids [8–10]. Initially,
PPARs were thought mainly to govern lipid homeostasis by
binding fatty acids and their metabolites to thereby become
more active in regulating genes for proteins involved in
lipid metabolism [8, 10, 11]. Indeed, PPARα is expressed
predominantly in tissues with high fatty acid requirements
such as liver, heart, and kidney, while PPARγ isoforms γ1
and γ2 are highly enriched in adipose tissue to regulate
adipocyte diﬀerentiation and lipid storage [3]. However,
expression of PPARγ1, as with PPARβ/δ and PPARα,h a s
n o wb e e ne x t e n d e dt om o s to t h e rt i s s u e sa n dr e g u l a t o r y
roles for PPARs extended to other systemic functions such
as carbohydrate regulation, immune modulation, and the
proliferation, survival and diﬀerentiation of cells [3]. The
latter eﬀects have led to intense interest in the PPARs in
relation to cancer.
PPARα and its ligand activators regulate fatty acid
and lipoprotein metabolism and promote the development
of hepatocellular carcinoma in rodents and reduce the
metastasis of melanoma in hamsters [12]. These and other
of their eﬀects do not, in general, translate to humans.
PPARβ/δ plays a key role in lipid metabolism of peripheral
tissues. Its high expression in colon has been shown to
promote colon cancer [12, 13], in a mechanism that involves
the stimulation of PPARβ/δ by arachidonic acid, PPARβ/δ-
dependent upregulation of cyclooxygenase (COX)-2 leading
to overproduction of prostaglandin (PG)E2,a n dP G E 2-
induced growth of colon cancer cells. There is relatively
little documentation of a role for PPARβ/δ in other cancers
[14]. By contrast, PPARγ has a broad range of eﬀects on
cancer. PPARγ controls fat metabolism by regulating genes
involved in lipogenesis, insulin sensitivity, and adipocyte
diﬀerentiation [3, 15]. These eﬀects underlie the use of
thiazolidinediones, which bind and activate PPARγ,t ot r e a t
insulin-resistant type II diabetes [3, 15]. Although PPARγ
activators have been widely shown to inhibit growth in2 PPAR Research
cultured cancer cells, in vivo eﬀects have proved to be
complex: they inhibit but sometimes promote cancer growth
[16] probably due to stimulation of antiproliferative and
apoptotic signaling pathways or proliferative and antiapop-
totic pathways, depending on cellular conditions [3, 12,
15–18]. These ﬁndings led to the idea of selective PPARγ
modulators (SPARMs), drugs analogous to selective estrogen
receptor modulators (SERMs) in which distinct actions of
the modulator depend on the cellular context [19]a n do n
distinct receptor conformations, and therefore diﬀerent gene
interactions [20] .F a t t ya c i d sm a yb ec o n s i d e r e da sn a t u r a l
SPARMs since their binding does not necessarily lead to
PPAR activation and target gene transcription [11].
The considerations discussed above raise a possibility
that managed alterations in the type of fatty acids in tissues,
can alter the activity of PPARs and thereby the genes they
control for therapeutic beneﬁt. The fatty acid content of
tissues is dependent mainly on dietary intake. Omega-3
PUFAs, docosahexaenoic acid (DHA), and eicosapentaenoic
acid (EPA) are enriched in the diets of many populations
that enjoy a low incidence of cancer [21]. These diets also
obtain some modest success ameliorating advanced cancer
in humans [22] and have been widely used to inhibit
carcinogenesis and tumor progression in animal models.
The ability of speciﬁc fatty acids to diﬀerentially activate
PPARs and PPAR-regulated genes may be central to their
distinct roles in cancer. This review will focus on PPARγ,i t s
activationbyfattyacids,andfunctionalresultsincancercells.
2. FATTY ACID METABOLISM
2.1. Fattyacidtypesandinterconversions
Fatty acids are hydrocarbons with a terminal carboxyl group.
The carbons of saturated fatty acids are all connected by
single bonds, whereas the chains of monounsaturated and
polyunsaturated fatty acids (PUFAs) contain one or more
double bonds, respectively. The n-3 and n-6 designation
describes the position of the double bond closest to the
(omega)carbonatthemethylendofthemolecule(Figure 1).
O l e i ca c i d( 1 8:1 )h a sas i n g l ed o u b l eb o n db e t w e e nc a r b o n s
9 and 10 from the omega carbon and is designated an n-9 or
omega-9monounsaturatedfattyacid.Likethesaturatedfatty
acids, oleic acid can be synthesized de novo in mammalian
cells. It can also be obtained from the diet through intake of
oils such as olive and canola. By contrast, PUFAs cannot be
synthesized de novo in mammalsand must be obtained from
the diet. The shortest of the n-6 PUFAs is linoleic acid (LA,
18 : 2, n-6). Its 18 carbon, n-3 counterpart is α-linolenic acid
(ALA,18:3,n-3).BothLAandALAaremetabolizedthrough
a series of elongation and desaturation steps to longer chain
PUFAs: LA to arachidonic acid (AA, 20 : 4, n-6) and ALA
to EPA (20 : 5, n-3) and DHA (22 : 6, n-3) (Figure 2). The
ﬁrst and rate limiting step in this pathway is the introduction
of a double bond by the Δ6 desaturase (for review see [23]).
For n-3 PUFAs, ALA is converted to stearidonic acid (SDA,
18 : 4, n-3), elongated, and desaturated by Δ5-desaturase
to form EPA. In mammalian cells, the conversion of EPA
to DHA follows the Sprecher pathway in which EPA is
elongated to docosapentaenoic acid (DPA, 22 : 5, n-3),
then to tetracosapentaenoic acid (TPA. 24 : 5, n-3), and
desaturated to tetracosahexaenoic acid (THA, 24 : 6, n-
3). THA is translocated from the endoplasmic reticulum
to peroxisomes, where β-oxidation results in the loss of 2
carbons to form DHA [24]. The PUFAs are also metabolized,
most importantly for this review, to PPARγ activators (see
Section 2.3).
2.2. Dietaryfattyacids
The results of both dietary intake and stable isotope studies
have shown that the conversion of ALA to DHA in humans
is extremely ineﬃcient (for review see [25]). Most of the
ingested ALA is an immediate target for β-oxidation to
provide energy, leaving an estimated 8–10% to enter the
elongation-desaturation pathway [26, 27]. A kinetic analysis
of 2H-labeled fatty acids estimated that conversion of ALA
to EPA was only 0.2%, EPA to DPA was 0.13%, and
DPA to DHA was 0.05% [28] .T h e r ei ss o m ee v i d e n c eo f
gender-related diﬀerences in the activity of the elongation-
desaturation pathway that result in a greater eﬃciency of
conversion of ALA to DHA in females than in males [25, 27,
29]. Support for a role of sex hormones in the conversion
pathway is provided by data indicating higher DHA in
plasma lipids associated with oral contraceptive use [27]a s
well in males supplemented with estrogen during sex-change
procedures[30].Moreover,testosteronetreatmentoffemale-
male transsexuals was shown to decrease plasma DHA [30].
Because common enzymes in the elongation-desatu-
ration pathway are responsible for conversion of both n-3
and n-6 PUFAs, background diet is also a factor in eﬃciency
of conversion. LA is the most abundant fatty acid in the
Western diet with consumption in US that is ten-fold that
of ALA (reviewed in [31]). Studies have shown that a high
intake of LA is associated with a low conversion of ALA to
EPA [26]. In spite of limited metabolism of ALA to its long
chain derivatives in the stable isotope tracer studies, feeding
studies have consistently shown that increased consumption
o fA L Ad o e sr e s u l ti nh i g h e rl e v e l so fE P Ai np l a s m ao rc e l l
lipids [31]. However, there was no measurable increase in
DHA in these pools. Likewise diets supplemented with EPA
do not result in a detectable increase in plasma DHA [32].
Thus,theineﬃciencyofthispathwaydoesnotappearlimited
to one step but rather extends throughout the pathway. The
consensus of a number of studies is that the only way to
increase plasma and tissue levels of a speciﬁc PUFA is to
increase the consumption of that fatty acid. This may be of
particular importance in the light of recent in vitro studies
on the antitumor eﬀects of DHA.
2.3. PUFAsmetabolismtoPPARγ activators
Tissues metabolize PUFAs to oxygenated products that
have quite diﬀerent impacts on PPARγ than their parent
molecules. Moreover, n-3 PUFA inhibit the metabolism n-6
PUFAs and subplant them from their oxygenation pathways
to form products [33–35] that have diﬀerent eﬀects on
PPARγ than their n-6 PUFAs oxygenated counterparts.I. J. Edwards and J. T. O’Flaherty 3
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Figure 1: Structures of unsaturated fatty acids: oleic acid (n-9 monounsaturated), linoleic acid and arachidonic acid (n-6 polyunsaturated),
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Figure 2: The elongation-desaturation pathway for the metabolism of n-6 and n-3 polyunsaturated fatty acids.4 PPAR Research
It is therefore important to consider PUFAs oxygenation
pathways. LA, AA, and DHA require >10–30μMt oa c t i v a t e
PPARγ but are commonly converted to stronger (>0.1–
10μM) activators in cells. LA is metabolized (Figure 3,u p p e r
panel) by 15-lipoxygenases (LOX)-1/2 to 9(S)- and 13(S)-
HODE (hydroxy-octadecaenoate) and by cyclooxygenases
(COX)-1/2 to 9(R)- and 13(S)-HODE. The HODEs can be
converted to 13-oxo- and 9-oxo-ODE by a dehydrogenase
[36–39]. The hydroxy and to a greater extent oxo LA analogs
have greater PPARγ-activating potency than LA [36, 40–
42]. AA is metabolized (Figure 3,c e n t e rp a n e l )v i a5 - L O X
to5(S)-HETE(hydroxy-eicosatetra-enoate)andvia15-LOX-
1/2 to 15(S)-HETE. These HETEs can be converted to oxo-
ETEs and 5-oxo-15(S)-hydroxy-ETE as shown in Figure 3
[39, 43–50]. 15-HETE has weak and 5-HETE essentially no
ability to activate PPARγ. However, their oxo counterparts
have appreciable ability to do so with 5-oxo-15(S)-hydroxy-
ETE showing the greatest potency in binding and activating
PPARγ [43]. AA is also metabolized (Figure 3,c e n t e rp a n e l )
byCOX1/2toPG(prostaglandin)D2 whichasaconsequence
of successive dehydrations and an isomerization, perhaps
by nonenzymatic routes, convert to PGJ2, Δ12-PGJ2,a n d
15-deoxyΔ12,14-PGJ2(15-d-Δ12,14-PGJ2); these PGJ2’s have
greater ability than PGD2 to activate PPARγ with 15-
d-Δ12,14-PGJ2 being a most potent (>0.1–1μM) naturally
occurring PPARγ activator [9, 43, 51–56]. In one study, the
Kd’s of 15-d-Δ12,14-PGJ2, 5-oxo-15-OH-ETE, PGJ2, 5-oxo-
ETE, and 5(S)-HETE in binding to PPARγ were 1.4, 11, 37,
81, and >1000μM, respectively; their potency in activating
a cell-based PPARγ reporter paralleled these Kd’s [43]. DHA
is metabolized (Figure 3, bottom panel) by 15-LOX or other
oxygenaseto17-OH-and7-OH-DHA,productsthatactivate
PPARγ with greater potency (ED50’s in activating a cell-
based PPARγ reporter of ∼5μM) than DHA [57]. 4-OH-,
and 4-oxo-DHA [53], while not yet shown to be made
by cancer cells, also activate PPARγ with greater potency
(ED50’s of 13.4 and 7.8μM in activating a cellular PPARγ
reporter, resp.) than DHA (ED50 > 10μm) [53]. Hence,
in this DHA series, similar to the 5-HETE series of AA
metabolites, the oxo analog exhibits the greatest potency.
We note that the more potent PPARγ activators, the oxo-
PUFAs, form preferentially in cells undergoing excessive
oxidation, free radical, and NADPH/NADH-depleting reac-
tions [43, 44, 48, 57, 58]. This suggests that PPARγ may
serve as a sensor for oxo-PUFA thereby monitoring cellular
oxidative stress and when this stress is severe, engaging
cell death programs [43, 58]. This PPARγ function, we
suggest, could contribute to the necrosis that occurs in
tumors particularly after chemical and radiation treatment
[59].
Cells process PUFAs in other relevant ways. They convert
them to nitrates, probably in nonenzymatic reactions, where
the nitric oxide made during cell stimulation attacks the
PUFAs. Nitrated LA and AA are stronger PPARγ activators
than their precursors [60–62]. Cells also convert PUFAs to
cannabinoids such as anandamide (ethanolamine amide of
AA) and arachidonoylglycerol which also activate PPARγ
with greater potency than AA [63–65]. Finally, cells conju-
gate glutathione to PUFAs that contain an α,β-unsaturated
ketone such as 15-d-Δ12,14-PGJ2 and 5-oxo-ETE [66–68].
Since the conjugates are rapidly excreted from cells by
multidrug-resistance transporters, conjugation inhibits the
ability of α,β-unsaturated ketones to activate PPARγ [66].
Cancer cells excrete anticancer drugs through these same
transporters and become drug-resistant by overexpressing
these transporters [69]. Such mutated cells may also be
resistant to α,β-unsaturated ketone activators of PPARγ.
2.4. Low-densitylipoproteins(LDL)asdeliverersof
PPARγ-activatingn-3PUFA
LDL carry esteriﬁed PUFAs in glycerolipids and cholesterol.
They bind to cell surface LDL receptors and then internalize
in endocytic vesicles which merge with lysosomes to de-
esterify and release the PUFAs into the cytosol [70]. This
route diﬀersfromthedirectdeliveryofPUFA:itbypassescell
surface G protein-coupled fatty acid receptors (GPR 40 and
120;seeSection 4.3),depositsPUFAincellsmoreslowly,and
thereby avoids stimulation of G protein-coupled receptors
and, perhaps, an array of C domain-bearing proteins which
are activated by PUFA. This is also an important pathway
for delivering PUFA to tumor cells because of a signiﬁcant
increase in LDL receptor activity in neoplastic tissues [71–
73]. We have obtained from monkeys fed special diets, LDL
enriched with n-6 PUFA (mostly AA and LA) or n-3 PUFA
(mostlyDHAandEPA).Then-3butnotn-6PUFA-richLDL
mimicked thiazolidinediones and DHA in inhibiting cancer
cell growth [74] and activating PPARγ [75, 76].
3. PPARγ
3.1. Structuralconsiderations
PPARγ1a n dγ2 originate from the PPARγ gene through
separate promoters and 5  exons. Compared to the ubiqui-
tously expressed PPARγ1, PPARγ2, which is limited mainly
to adipose tissue, has 30 additional amino acids at its NH2
terminus and is a more potent transcription activator [77].
Because they appear to have the same targets, however,
the two isoforms are here considered together under the
term PPARγ.P P A R γ is comprised of four functional parts:
the NH2-terminal A/B region bears a ligand-independent
transcription-activating motif AF-1; Cregionbinds response
elements (PPREs with a DR-1 consensus half-sequence of
AGGTCA); D region binds various transcription cofactors;
and E/F region has an interface for dimerizing with 9-cis
retinoic acid receptors (RXRs), an AF-2 ligand-dependent
transcription-activating motif, and a ligand-binding domain
(LBD) [3, 12, 15, 17]. The LBD has a spacious cavity
that binds ligands having a polar head group extending
from a hydrophobic tail such as diverse PUFAs and PUFA
metabolites [7, 77].
3.2. PPARγ regulationbyothersignalingpathways
PPARγ is phosphorylated by extracellular signal-regulated
kinases (ERK)-1/2 and C-Jun N-terminal kinase; when soI. J. Edwards and J. T. O’Flaherty 5
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phosphorylated, it has less ligand-binding aﬃnity and gene-
regulating activity [3, 78, 79]. The phosphorylation and
attendant decrease in activity of PPARγ occur in cells treated
with PPARγ activators and may cause the activators to show
little or no ability to stimulate PPARγ [3, 79–81]. ERK
pathways impact PPARγ in another way: the ERK-activating
enzyme, MEK, when activated, binds with PPARγ’s AF-2
motif. This causes PPARγ to release from PPRE complexes
and, bound to MEK and directed by MEK’s nuclear export
signal,toexitthenucleus[81,82].Itisimportanttonotethat
PUFAs and PUFA metabolites can activate the MEK/ERK
pathway (see Section 4.3) and therefore may have biphasic
eﬀects: they not only directly activate PPARγ but also entrain
events inhibiting PPARγ.
PPARγ is targeted for degradation by ubiquitylation
and sumoylation. Ligand binding, certain protein kinases,
and some transcription cofactors (e.g., p300) promote
ubiquitin-dependent degradation of PPARγ in proteasomes
[3] .S u m o y l a t i o no c c u r so nK 1 0 7o fP P A R γ2 in a ligand-
independent fashion to inhibit AF-1 function and on K365
of PPARγ in a ligand-dependentfashiontopromote PPARγ’s
binding of nuclear receptor corepressor [83, 84]. Sumoy-
lation of PPARγ causes its proteasomal degradation. ERK
phosphorylation promotes K107 sumoylation. This reaction
represents yet another means by which ERKs can inhibit
PPARγ [84].
3.3. PPARγ transcriptionalcofactors
PPARs bind a speciﬁc DNA sequence termed peroxisome
proliferator response element (PPRE) in the 5 -ﬂanking
region of target genes as a heterodimer with RXR. Studies
using various techniques [3, 85, 86] suggest the following
model: PPARγ•RXR complexes (the interaction is ligand-
independent) exist in nuclei as macrocomplexes associ-
ated with various transcription corepressors [3, 87]. Some
complexes, ligand-bound or not, may associate with tran-
scription coactivators to control the basal expression of
genes. In any event, PPARγ•RXR complexes are highly
mobile, rapidly scanning chromatin, although this scan-
ning does not involve their DNA binding domain [86].
Ligands trigger PPARγ•RXR to localize at their cognate
PPREs and to exchange corepressors for coactivators such
as cyclic AMP response element binding protein (CREB)
and p300 [3, 16, 87, 88]. At some gene sites, activators
cause PPARγ•RXR to recruit corepressors and thereby cause
gene repression [3, 89, 90]. However, the availability of
cofactors diﬀers between cell types and within cells over
time depending on the cell’s history and the association
of the cofactors to other genes [3, 15, 16], for exam-
ple, activation of PPARγ deprives T cell factor/lymphoid
enhancing factor (TCF/LEF) of cofactors to thereby inhibit
oncogenic signaling by the Wnt pathway [16]. Thus, the
eﬀects of PPARγ activation vary depending on context
and cofactor availability at each genetic site. It seems at
least possible that the PUFA ligands for PPARγ will have
diﬀerential eﬀects in impacting its interactions with these
transcriptional cofactors in a manner similar to the SPARMs
model [19].
4. TARGETS OF PPARγ RELEVANT TO CANCER
4.1. GenetargetsofPPARγ
MostknowntargetgenesofPPARγ regulatelipidmetabolism
and transport [15]with few cancer-related genes having been
conﬁrmed as induced by PPARγ.P P A R γ does induce G0/G1
switch gene 2 whose product causes growth arrest in 3T3-
L1 cells [91, 92]. PPARγ also binds the NFκBp r o m o t e ro f
p53 to stimulate expression of p53 and, in consequence,
p21WAF1/Cip1. It also binds to a promoter in the Fas ligand
gene to induce the expression of this member of the extrinsic
apoptosis pathway. These eﬀects appear responsible for
slowinggrowthandcausingapoptosisinMCF7breastcancer
[93], human umbilical vein endothelial [94], and possibly
Reh [95] cells. Recent studies have identiﬁed the heparan
sulfate proteoglycan, syndecan 1, as a target for PPARγ in
human breast [75, 76] and prostate [96] cancer cells. The
upregulation of syndecan 1 by PPARγ resulted in apoptosis
induction [76].
4.2. OthertargetsofPPARγ
PPARγ impacts many growth-promoting elements through
its secondary actions that, while ligand-dependent, do not
directly involve its gene promoters. It interacts with nuclear
factor of activated T cells, phosphorylated signal transducer,
and activator of transcription (STAT)-3, and nuclear factor
κB( N F κB) to block signaling through these pathways [3].
It binds transcription cofactors to alter these cofactors’
availability to other transcription factors: ligand bound-
PPARγ deprives NFκB of AP-1; deprives STAT-1 of CREB
binding protein; and releases SMRT to render it available
to repress STAT-3’s transcriptional activity [3, 16, 17, 97].
PPARγ activation is also associated with the activation of
ERK1/2, protein kinases C, protein kinase A, AMP-activated
protein kinase α [17]; induction of p16, p18, and p21 cyclin-
dependent kinase inhibitors [3, 17, 18]; decreased expression
of cyclooxygenase 2, cmyc, cmyb,D 1 ,a n dD 3c e l lc y c l e
control genes, and regenerating gene 1A [17, 18]; decreased
secretionofcytokinesandgrowthfactors[17,98];depression
of the Akt survival pathway by upregulating PTEN and
inhibiting the phosphorylation of Akt and mTOR [3, 17];
inhibiting retinoblastoma protein (Rb) activity to repress the
activities of cyclins D3 and E [3]; and regulating a host of
other elements involved in the growth and death of cells
[3, 12, 16–18]. It is not clear which if any of these eﬀects
are due to the action of PPARγ or PPARγ activators. PUFAs
impact many of these same targets but can do so not only by
PPARγ-dependent but also PPARγ-independent routes (see
the next section).
4.3. TargetsofPPARγ-activatingLigands
Studies of PPARγ function depend on challenging cells with
PPAR-activating ligands that have numerous side eﬀects
impacting cell growth. 15-d-Δ12,14-PGJ2 has a reactive α,β-
unsaturated ketone (Figure 3) that covalently binds to cys-
teine sulfur on PPARγ; this renders its PPARγ binding irre-
versible [58, 68]. 15-d-Δ1,14-d-PGJ2 also binds to cysteinesI. J. Edwards and J. T. O’Flaherty 7
in the IKKβ subunit of IκB kinase, thereby inhibiting NFκB
activation [99, 100]. Other ligands with an α,β unsaturated
ketone(e.g.,oxo-ODEsandoxo-ETEs;seeFigure 3)havethis
chemical reactivity [58] and along with 15-d-Δ1,14-d-PGJ2
may exert anticancer eﬀects by covalently attaching to signal
molecules like IKKβ [58, 99, 101] or elements needed for
expressing the epidermal growth factor receptor (EGFR) and
JAK [102, 103].
Naturally occurring ligands have other PPARγ-inde-
pendent eﬀects. The D and J series of PGs including 15-
d-Δ12,14-PGJ2 bind to PGD2 receptors [104], 5-oxo- and 5-
oxo-15-hydroxy-ETE bind to the OXE receptor [105], and
AA, EPA, and DHA bind to GPR40 and GPR120 receptors
[106,107].TheseGprotein-coupledreceptorsregulatesignal
pathways that eﬀect cancer cell growth. For example, 5-oxo-
15-hydroxy ETE acts on OXE to stimulate cells to activate
ERK and Akt and proliferate; this stimulation counters its
antigrowth activity in various cancer cell types. Indeed,
HEK293 cells lack OXE receptors and in contrast to OXE
receptor-bearing breast, prostate and ovarian cancer cell
lines respond to 5-oxo-ETE and 5-oxo-15-oxo-ETE only
by slowing, not speeding, their proliferation [43]. PUFAs
activation of GPR120 also causes ERK and Akt activation
to increase the survival of serum-starved STC-1 cells [108].
Finally, PUFAs are also metabolized to products that act on
G protein receptors to promote cell growth, for example,
prostate cancer cells convert AA to PGE2, which acts through
its receptors to stimulate the NFκB pathway and thereby the
expression of various cytokines and growth factors [109].
The G protein receptor-dependent actions of PPARγ ligands
mayexplainreportsthattheseligandshavebiphasiceﬀectsin
stimulating proliferation and antiproliferation in cancer cells
[110].
Thiazolidinediones stimulate cells to activate ERK1/2,
p38, and JNK [111–113] by discharging Ca2+ from the ER to
evoke an ER stress response; this activates Ca2+/calmodulin
kinase II, proline-rich tyrosine kinase 2, protein kinases C,
c-Src, EGFR, the ERK1/2 and JNK pathways, the double
stranded RNA-activated protein kinase, and p38 [111].
Double stranded RNA-activated protein kinase inactivates
eukaryotic initiation factor-2 to depress protein translation
[111, 114]. Since EPA has recently been shown to have
similar eﬀects on ER calcium discharge [111, 115], it seems
likely that various other PUFAs activate the ER stress
pathway. Nonetheless, PPARγ activators often show very
diﬀerent side eﬀects [42, 103, 116–120]. For example, among
three PPARγ agonists, ciglitazone, 9-HODE, and 13-HODE,
only 9-HODE induced apoptosis in U937 cells [38], 15d-
Δ12,14-PGJ2, but not various other PPARγ ligands, reduced
EGFR expression in squamous carcinoma cells [99], 15d-
Δ12,14-PGJ2, but not troglitazone, inhibited the stimulated
induction of MHC class II molecules in retinal pigmented
epithelial cells [112], and DHA, but not EPA, stimulated
the target gene, syndecan 1 to inhibit the proliferation and
induce apoptosis in breast and prostate cancer cell lines
[75, 76, 96]. Numerous other examples of diﬀerential eﬀects
among PPARγ agonists exist (e.g., [113–116]), but it is worth
stressing that n-3 PUFAs inhibit the metabolism of n-6
PUFAs to products that promote the growth of cancer cells
such as PGE2, 5-HETE, and leukotriene B4 [33–35, 45, 113].
This inhibitory eﬀect may make an important contribution
to the anticancer eﬀects of n-3 PUFAs.
5. DIETARY FATTY ACIDS AND CANCER
5.1. Humanstudies
Although there are inconsistencies [121], human population
studies have shown that consumption of a diet enriched in
n-3 PUFAs may oﬀer protection against a number of cancers
including those of breast [122–124], prostate [125, 126], and
colon [127–129]. Although many of these studies have relied
on dietary intake data from self-reported questionnaires or
estimates based on national consumption, a few have used
thefattyacidcompositionoftissuesasameasureofexposure
to dietary fats. The EURAMIC study is one of the largest
to provide evidence that the balance between n-3 and n-
6 PUFA may play a role in breast cancer [130]. Adipose
tissue aspirates from breast cancer patients and controls
demonstrated that the ratio of long chain n-3 to n-6 PUFAs
was inversely associated with breast cancer in four of ﬁve
centers studied. In human prostate tissue, lower EPA and
DHAaswellaslowern-3ton-6PUFAsratioswereassociated
with cancer compared to benign prostate hyperplasia [131]
and with advanced stage compared to organ conﬁned disease
[132]. This inverse association of n-3 PUFAs and prostate
cancer is supported by analyses of fatty acids in serum
and red-cell membranes of patients with prostate disease
[133, 134].
5.2. Animalstudies
Animal studies provide convincing evidence of a negative
relationship with n-3 PUFA diets and a positive relationship
with n-6 PUFA diets for breast, prostate, and colon cancer.
In studies of breast cancer induced by chemical carcinogens
in rats [135–137], and human cancer cell xenografts in nude
mice [138–140], tumor growth rate, size, and metastases
were all suppressed by dietary n-3 PUFA supplementation.
Likewise for colon cancer, antitumor properties of n-3 PUFA
dietshavebeenshownintransplantablemousetumors[141–
143]a sw e l la si nc h e m i c a l l yi n d u c e dr a tt u m o r s[ 144–151].
Although there have been fewer animal studies of PUFAs
in prostate cancer, they are consistent with those in breast
and colon cancer. In xenograft models of prostate cancer, n-
3 PUFAs enriched diets inhibited tumor growth compared
to n-6 PUFA diets [152–154]. Recently, a prostate-speciﬁc
Pten knockout mouse model was used to demonstrate that
a dietary ratio of n-6 to n-3 PUFA lower than 5 was eﬀective
in suppressing tumor growth, and extending animal lifespan
[155].
5.3. Cellculturestudies
Insight into the mechanism(s) responsible for the anticancer
properties of n-3 PUFAs have been provided by animal
studies as well as by in vitro investigations using human
cancer cell lines. A major focus for such studies has been8 PPAR Research
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Figure 4: The syndecan-1 pathway for n-3 PUFA induction of
apoptosis. Dashed lines indicate that eﬀects may be indirect with
involvement of other metabolites and signaling molecules.
the competitive inhibition between n-6 and n-3 PUFAs for
the enzymes involved in their metabolism. The desaturation
and elongation of LA to AA were shown to be decreased in
the presence of high n-3 PUFAs due to enzyme preference
for the n-3 substrates [156]. AA and EPA compete for
the COX and LOX enzymes, again with preferential n-3
utilization that results in a reduction in the highly reactive
eicosanoids generated from AA [157, 158] in favor of less
inﬂammatory n-3 eicosanoids [159]. The decreased growth
ofprostatexenografttumorswasshowntoinvolveinhibition
of COX 2 and PGE2 in the tissues [154]. Thus, the combined
human, animal, and cell culture studies indicate that diet
is an important regulator of the levels of n-3 versus n-6
PUFAs in tissues, including those that are cancerous. High
levels of n-3 PUFAs may directly evoke antitumor events,
become metabolized to products with antitumor activity,
or suppress the production of tumor-promoting metabolites
such as those formed by n-6 PUFAs.
6. n-3 PUFA REGULATION OF SYNDECAN-1
IncreasingevidenceimplicatesPPARγ inthedivergenteﬀects
of n-3 and n-6 PUFAs in cancer cells and point to a
growth inhibitory role for PPARγ [160–164]. We recently
found that n-3 PUFAs—but not n-6 PUFAs—enriched LDL,
inhibited the proliferation, and induced apoptosis in human
breast cancer cells [74–76]. The n-3 LDL delivered both
EPA and DHA to the cells. When these individual fatty
acids were delivered to cells by albumin, DHA but not EPA
proved eﬀective in stimulating apoptosis in a pathway that
involved activation of PPARγ [75]. The molecular target for
both DHA and PPARγ in these cells was shown to be the
heparan sulfate proteoglycan, syndecan-1. Syndecan-1 itself
was eﬀective in apoptosis induction and when syndecan-1
was silenced, the ability of DHA to induce apoptosis was
completely blocked as it was in the presence of a dominant
negative PPARγ [76]. Moreover, syndecan-1 siRNA was
eﬀective in blocking troglitizone-induced apoptosis. Thus,
a novel pathway linking n-3 PUFAs to apoptosis in tumor
cells is as follows: DHA activates PPARγ, which results in
transcriptional upregulation of the syndecan-1 target gene,
and the syndecan-1 protein induces apoptosis (Figure 4).
T h i sn o v e lp a t h w a yh a sb e e nc o n ﬁ r m e di nh u m a np r o s t a t e
cancer cells [96].
Although PPARγ w a sn o tat a r g e tf o rE P Ai nb r e a s t
and prostate cancer cells, a recent report has demonstrated
that EPA was an eﬀective PPARγ transactivator in HT-
29 human colon cancer cells [165]. In contrast, both EPA
and DHA were shown to reduce PPRE reporter activity in
an HCT-116 colon cancer cells [166]. DHA has recently
been shown to reduce the growth of human lung cancer
cells in a process that was associated with increased PPARγ
protein [167]. These conﬂicting reports are consistent with
data showing selective modulation of PPARγ by diﬀerent
ligands in diﬀerent cells [168]. Several other reasons may
be proposed for the diﬀerential response to DHA and EPA
in the breast and prostate tumor cells including (1) PPARγ
activation may be mediated by a unique DHA metabolite
rather than DHA itself; (2) there may be a diﬀerence in the
bioavailabilityofthetwofattyacidsfollowingcellularuptake;
(3) EPA may be a ligand for or metabolized to a ligand
(e.g., 5(S)-hydroxy-eicosapentaenoic acid) for a G protein-
coupled receptor that activates ERK and thereby inactivates
or in some other way counteracts PPARγ;( 4 )E P Am a y
directly, or after being metabolized, activate other pathways
that counteract PPARγ signaling.
The identiﬁcation of syndecan-1 as a target gene for
PPARγ in the breast and prostate cancer cells was a novel but
not unexpected ﬁnding. The syndecan-1 promoter contains
a DR-1 element that is recognized by a several members
of the nuclear hormone receptor superfamily including
PPARγ. Although there are conﬂicting reports of a role for
syndecan-1 in cancer, the importance of these studies is the
identiﬁcation of a PPARγ molecular target that is regulated
by PUFAs and results in functional response in the tumor
cells. As more such targets emerge, we may be able to
understand how diﬀerent dietary fatty acids play divergent
roles in cancer.
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